Foghorn Therapeutics, Inc. (FHTX): Price and Financial Metrics
FHTX Price/Volume Stats
| Current price | $6.52 | 52-week high | $9.97 |
| Prev. close | $6.81 | 52-week low | $2.70 |
| Day low | $6.26 | Volume | 115,300 |
| Day high | $6.78 | Avg. volume | 221,267 |
| 50-day MA | $5.05 | Dividend yield | N/A |
| 200-day MA | $6.04 | Market Cap | 275.25M |
FHTX Stock Price Chart Interactive Chart >
FHTX POWR Grades
- Sentiment is the dimension where FHTX ranks best; there it ranks ahead of 87.35% of US stocks.
- The strongest trend for FHTX is in Growth, which has been heading up over the past 26 weeks.
- FHTX's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
FHTX Stock Summary
- FOGHORN THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 6.11% of US listed stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -10.9 for FOGHORN THERAPEUTICS INC; that's greater than it is for only 2.28% of US stocks.
- As for revenue growth, note that FHTX's revenue has grown 106.7% over the past 12 months; that beats the revenue growth of 95.66% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to FOGHORN THERAPEUTICS INC are MTEM, AGEN, SEEL, ARAV, and APLT.
- FHTX's SEC filings can be seen here. And to visit FOGHORN THERAPEUTICS INC's official web site, go to foghorntx.com.
FHTX Valuation Summary
- In comparison to the median Healthcare stock, FHTX's price/sales ratio is 100% higher, now standing at 8.4.
- Over the past 39 months, FHTX's EV/EBIT ratio has gone up 10.9.
Below are key valuation metrics over time for FHTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FHTX | 2023-12-29 | 8.4 | -4.7 | -2.6 | -2.5 |
| FHTX | 2023-12-28 | 8.8 | -5.0 | -2.8 | -2.6 |
| FHTX | 2023-12-27 | 8.6 | -4.9 | -2.7 | -2.5 |
| FHTX | 2023-12-26 | 8.6 | -4.9 | -2.7 | -2.5 |
| FHTX | 2023-12-22 | 8.7 | -4.9 | -2.7 | -2.6 |
| FHTX | 2023-12-21 | 8.1 | -4.6 | -2.6 | -2.4 |
FHTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- FHTX has a Quality Grade of C, ranking ahead of 42.73% of graded US stocks.
- FHTX's asset turnover comes in at 0.005 -- ranking 410th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows FHTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.005 | 1 | -0.469 |
| 2020-12-31 | 0.003 | 1 | -0.581 |
FHTX Price Target
For more insight on analysts targets of FHTX, see our FHTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.67 | Average Broker Recommendation | 1.38 (Strong Buy) |
Foghorn Therapeutics, Inc. (FHTX) Company Bio
Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.
Latest FHTX News From Around the Web
Below are the latest news stories about FOGHORN THERAPEUTICS INC that investors may wish to consider to help them evaluate FHTX as an investment opportunity.
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's WhyFoghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%The average of price targets set by Wall Street analysts indicates a potential upside of 160.6% in Foghorn Therapeutics Inc. (FHTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual MeetingCAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held |
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Price Is Right But Growth Is Lacking After Shares Rocket 27%Those holding Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shares would be relieved that the share price has rebounded 27... |
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsFlagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo |
FHTX Price Returns
| 1-mo | 69.79% |
| 3-mo | 58.64% |
| 6-mo | -9.32% |
| 1-year | 7.77% |
| 3-year | -60.48% |
| 5-year | N/A |
| YTD | 1.09% |
| 2023 | 1.10% |
| 2022 | -72.10% |
| 2021 | 12.83% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...